Home › Research › Disease mechanisms
ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease
Matthew Paul Lennol, Chiara Bordier, Léana Kamelher, Jason D. Ulrich, David M. Holtzman, Maud Gratuze. The Journal of Experimental Medicine, 2025-08-05
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer's disease (AD), the most common cause of dementia, is characterized by the accumulation of amyloid-β (Aβ) in senile plaques and abnormally hyperphosphorylated tau proteins in neurofibrillary tangles. While much of the research has focused on Aβ, tau-mediated neurodegeneration is more closely associated with synaptic loss and cognitive decline in AD, emphasizing the need for a deeper understanding of tau pathology. In this context, the interaction between tau and APOE, particularly the main genetic risk factor for AD APOE ε4, remains underexplored. APOE encodes apolipoprotein E (apoE), a protein important in lipid metabolism. In addition to promoting Aβ deposition, emerging evidence suggests that APOE ε4 exacerbates tau-mediated neurodegeneration and tau-related pathology. This review consolidates current knowledge on the interplay between apoE and tau, highlighting its potential as a key factor in disease progression. Targeting the apoE-tau axis may offer promising therapeutic strategies to address the molecular mechanisms driving AD and primary tauopathies.
Key findings
- While much of the research has focused on Aβ, tau-mediated neurodegeneration is more closely associated with synaptic loss and cognitive decline in AD, emphasizing the need for a deeper understanding of tau pathology.
- In addition to promoting Aβ deposition, emerging evidence suggests that APOE ε4 exacerbates tau-mediated neurodegeneration and tau-related pathology.
Why it matters
This review summarizes evidence that APOE ε4 worsens tau-mediated neurodegeneration and tau-related pathology, in addition to promoting amyloid deposition. It suggests the apoE-tau interaction as a possible therapeutic target, but it is a review of existing knowledge and reports no tested treatment.
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of Experimental Medicine) |
| Journal's citation record | 4 / 4 | The Journal of Experimental Medicine: journal h-index 652 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 7.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Maud Gratuze: h-index 26 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40856646) |
| Free to read | 2 / 2 | Free to read |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1084/jem.20250965
- PubMed: 40856646
- Original source →
- Free full text: The Journal of Experimental Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Lennol, M. P., Bordier, C., Kamelher, L., Ulrich, J. D., Holtzman, D. M., & Gratuze, M. (2025). ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease. The Journal of Experimental Medicine. https://doi.org/10.1084/jem.20250965
Vancouver
Lennol MP, Bordier C, Kamelher L, Ulrich JD, Holtzman DM, Gratuze M. ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease. The Journal of Experimental Medicine. 2025. doi:10.1084/jem.20250965. PMID: 40856646.
BibTeX
@article{lennol2025-40856646,
author = {Lennol, Matthew Paul and Bordier, Chiara and Kamelher, Léana and Ulrich, Jason D. and Holtzman, David M. and Gratuze, Maud},
title = {{ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease}},
journal = {The Journal of Experimental Medicine},
year = {2025},
doi = {10.1084/jem.20250965},
pmid = {40856646},
url = {https://doi.org/10.1084/jem.20250965}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 103.
Related studies in Disease mechanisms
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.